"Adagio Therapeutics, a Waltham biotech, disclosed in a public filing Friday that it is planning to go public one year after it was founded to advance COVID-19 antibody therapies.

"The company, which spun out of New Hampshire-based Adimab, is developing drugs that aim to treat and prevent illness caused by the coronavirus, and by new variants.

"Although three COVID-19 vaccines have been authorized for emergency use by the Food and Drug Administration, it is Adagio's idea that the current pandemic will continue to require a 'variety of effective, safe and convenient treatment and prevention options for years to come,' according to a filing with the Securities and Exchange Commission."

..."Adimab, which licensed anticoronavirus antibodies to Adagio, is the largest stockholder in the firm, with a roughly 31 percent stake. Dartmouth professor and serial entrepreneur Tillman Gerngross is the cofounder and chief executive of both firms. Investors with more than a 5 percent stake in the company include Fidelity Management & Research Co., GV, Mithril, OrbiMed, Polaris Partners, and RA Capital."

Similar coverage in: MSN